1. Prediction for sustained deep molecular response of BCR‐ABL1 levels in patients with chronic myeloid leukemia in chronic phase
- Author
-
Sasaki, Koji, Kantarjian, Hagop, O'Brien, Susan, Ravandi, Farhad, Konopleva, Marina, Borthakur, Gautam, Garcia‐Manero, Guillermo, Wierda, William, Daver, Naval, Ferrajoli, Alessandra, Takahashi, Koichi, Jain, Preetesh, Rios, Mary Beth, Pierce, Sherry, Jabbour, Elias, and Cortes, Jorge E
- Subjects
Hematology ,Rare Diseases ,Cancer ,Adolescent ,Adult ,Aged ,Aged ,80 and over ,Antineoplastic Agents ,Female ,Follow-Up Studies ,Fusion Proteins ,bcr-abl ,Humans ,Leukemia ,Myelogenous ,Chronic ,BCR-ABL Positive ,Male ,Middle Aged ,Models ,Biological ,Prognosis ,Prospective Studies ,Protein Kinase Inhibitors ,Randomized Controlled Trials as Topic ,Treatment Outcome ,Young Adult ,best fit average ,chronic myeloid leukemia ,minimum acceptable ,molecular response with BCR-ABL1 level < 0.0032% on the international scale ,tyrosine kinase inhibitor ,molecular response with BCR-ABL1 level ,Oncology and Carcinogenesis ,Public Health and Health Services ,Oncology & Carcinogenesis - Abstract
BACKGROUND:The achievement of a sustained deep molecular response is a goal of increasing relevance because it opens the possibility of treatment discontinuation. The objective of this analysis was to develop a prediction model for a sustained molecular response with BCR-ABL1 level
- Published
- 2018